

**Department of Vermont Health Access
Pharmacy Benefits Management Program
DUR Board Meeting Agenda**

December 3, 2024: 6:00 – 8:30 p.m.

- **Executive Session** **6:00-6:30**
- **Introductions** **6:30-6:35**
(Public Comment Prior to Board Action)
- **DVHA Pharmacy Administration Updates** **6:35-6:45**
- **Chief Medical Officer Updates** **6:45-7:00**
- **Follow-up Items from Previous Meetings** **7:00-7:00**
 - None at this time.
- **RetroDUR/ProDUR** **7:00-7:10**
 - Data Presentation: The Effect of Trikafta on the Cost and Quality of Care of Patients with Cystic Fibrosis
- **Consent Agenda Items** **7:10-7:15**
 - **Approval Of DUR Board Minutes**
 - **Biosimilar Drug Review**
 - Tofidence™ (tocilizumab-bavi)
 - **Therapeutic Drug Classes – Periodic Review**
 - Smoking Cessation
 - Parathyroid Agents
 - Antihistamines (minimally sedating)
 - Leukotriene Modifiers
- **Review of Newly Developed/Revised Criteria** **7:15-7:30**
(Public comment prior to Board action)
 - None at this time.
- **Clinical Update: Drug Reviews** **7:30-8:00**
(Public comment prior to Board action)

Full New Drug Reviews

(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)

- Beqvez™ (fidanacogene elaparvovec-dzkt)
- Eohilia™ (budesonide oral suspension)
- Iqirvo® (elafibranor)
- Libervant™ (diazepam)

- Xolremdi™ (mavorixafor)

- **New Managed Therapeutic Drug Classes** **8:00-8:00**
 - None at this time.

- **Therapeutic Drug Classes – Periodic Review** **8:00-8:30**
(Public comment prior to Board action)
 - Alzheimer’s Agents
 - IBS/SBS/GI Agents
 - Intranasal Rhinitis
 - Sedative Hypnotics

- **General Announcements** **8:30-8:30**
 - None at this time.

- **Adjourn** **8:30 pm**